Table 5.

Association between lipid-lowering medication use and fatal prostate cancer stratified by race and plasma total cholesterol, men in ARIC (1990–2012)

Current use# Prostate cancer deathsPerson-yearsHRa (95% CI)HRb (95% CI)
Race
 White menNo3156,9731.0 (Ref)1.0 (Ref)
Yes2533,0290.60 (0.35–1.06)0.58 (0.33–1.04)
 Black menNo2217,0341.0 (Ref)1.0 (Ref)
Yes127,5050.76 (0.34–1.70)0.95 (0.42–2.15)
Pinteraction0.620.62
Total cholesterol
 Normal range (<5.2 nmol/L)No3244,1341.0 (Ref)1.0 (Ref)
Yes1314,9940.61 (0.31–1.21)0.61 (0.30–1.24)
 Borderline or elevated (≥5.2 nmol/L)No2129,7391.0 (Ref)1.0 (Ref)
Yes2425,5110.64 (0.33–1.27)0.67 (0.33–1.35)
Pinteraction0.780.72
  • aAdjusted for age and joint categories of race and field center.

  • bAdjusted for age, joint categories of race and field center, height, updated BMI, updated cigarette smoking status, updated diabetes status, updated aspirin use, and education level.